Keryx Biopharmaceuticals Inc., of New York, reported case study data at the American Society of Nephrology's Kidney Week meeting in Chicago, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis.